HELICOBACTER PYLORI CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE

ABSTRACT BACKGROUND: H. pylori chronic atrophic gastritis is a premalignant lesion, and its staging, according to OLGA OLGIM systems aims identify patients at increased risk of developing gastric cancer optimize their follow-up. GastroPanel®, serum biomarkers panel including pepsinogen I (PGI), II (PGII), Gastrin 17 (G17) anti- antibodies noninvasive test for adenocarcinoma assessment in patients. OBJECTIVE: Prospective study evaluate the concordance between grading systems, as well GastroPanel´s performance with lesions secondary Brazil. METHODS: Patients confirmed by histology were recruited from gastrointestinal clinic University Hospital. All participants underwent endoscopic examination biopsies which reported updated Sydney system (OLGA OLGIM). Blood samples collected serological analysis (GastroPanel®, Biohit, Helsinki, Finland). The cut off values used define high those recommended manufacturer: PGI ≤30 µm/L PGI/PGII ≤3. RESULTS: 41 recruited: 28 women, 13 men, mean age 67.3 (47-89, SD: 9.6) years. By system, obtained: 0 (n=1), (n=7), (n=17), III (n=9), IV (n=7). (n=14), (n=5), (n=10), (n=2). Regarding histological staging among staged low (OLGA/OLGIM 0, II) IV) development, rate found both classifications was 85.4%. Considering patients, thus included least one final distribution our sample considered 24 low-risk high-risk development cancer. To determine GastroPanel® whether patient would be or cancer, showed sensitivity, specificity accuracy 0.47 (95%CI: 0.26-0.69), 0.67 0.47-0.82), 0.58 0.43-0.72), respectively, while 0.06 0.01-0.27), 0.83 0.64-0.93) 0.51 0.36-0.66), respectively. CONCLUSION: presented substantial themselves. Simultaneous use classification identification’s Biomarker not effective distinguish studied population. Further studies are needed validate clinical practice